Boditech Med Inc. offers instruments and diagnostic reagents in South Korea and internationally. The company offers instruments, including ichroma II, diagnostic immuno-analyzer to measure the presence of various biomarkers for cardiac, cancer, hormones, infectious diseases, autoimmune diseases, and metabolic diseases; ichroma III, a high-throughput immuno-analyzer that enables simultaneous testing for various parameters; ExAmplar, a compact real time PCR that detects virus/bacteria quantitatively or qualitatively using ready-to-use cartridges; ichroma-50, an automated immunoassay system with high-throughput; Hemochroma PLUS, a handheld device that can run tests for anemia; portable analyzers ichroma M3 and ichroma M2; and NuActor, an automated nucleic acid extraction system. It also provides compact immunoassay analyzers, including AFIAS-1, AFIAS-3, AFIAS-6, and AFIAS-10; cardiac reagents; cancer reagents; COVID-19 reagents; diagnostic reagents; reagents for hormones, infections, autoimmune, organ functions, molecular diagnostics, therapeutic drug monitoring, and other test items. In addition, the company offers Ichroma TRIAS, ultra-high sensitivity respiratory disease diagnostic equipment; ALFIAS-3, a diagnostic equipment; and SyncNeb. Boditech Med Inc. was founded in 1998 and is headquartered in Chuncheon-si, South Korea.
Metrics to compare | 206640 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship206640PeersSector | |
|---|---|---|---|---|
P/E Ratio | 10.3x | 9.9x | −0.5x | |
PEG Ratio | 15.50 | 0.25 | 0.00 | |
Price/Book | 1.3x | 1.2x | 2.6x | |
Price / LTM Sales | 1.9x | 1.6x | 3.3x | |
Upside (Analyst Target) | 78.0% | 45.3% | 46.2% | |
Fair Value Upside | Unlock | 31.3% | 6.6% | Unlock |